Search research articles
Contact Us
Filters
Showing results (61-70 of 101) with videos related to
Page
of 11
Sort By:
Cancer
|
April 28, 2011
Prostacyclin synthase expression and epigenetic regulation in nonsmall cell lung cancer
Mary-Clare Cathcart, Steven G Gray, Anne-Marie Baird, et al.
Scientific Reports
|
July 26, 2019
Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide
John Greene, Anne-Marie Baird, Orla Casey, et al.
International Journal of Cancer
|
April 20, 2007
DOK4/IRS-5 expression is altered in clear cell renal cell carcinoma
Nael Al-Sarraf, Johanne Nørvig Reiff, Jane Hinrichsen, et al.
JAMA Network Open
|
March 9, 2022
Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma
Tomer Meirson, Francesca Pentimalli, Francesco Cerza, et al.
International Journal of Oncology
|
February 16, 2017
Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma
Sian Cregan, Maeve Breslin, Gerard Roche, et al.
International Journal of Oncology
|
March 9, 2005
Altered expression of members of the IGF-axis in clear cell renal cell carcinoma
Masayuki Takahashi, Veronica Papavero, Jason Yuhas, et al.
Plos One
|
January 10, 2013
Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression
Dario Barbone, Priscilla Cheung, Sailaja Battula, et al.
Molecular Cancer
|
January 29, 2020
Correction to: Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer
Martin P Barr, Steven G Gray, Kathy Gately, et al.
Molecular Cancer
|
April 19, 2015
Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer
Martin P Barr, Steven G Gray, Kathy Gately, et al.
Journal of Translational Medicine
|
December 13, 2022
Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology
Tomer Meirson, Valerio Nardone, Francesca Pentimalli, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 101) with videos related to
Sort By:
Page
of 11
Cancer
|
April 28, 2011
Prostacyclin synthase expression and epigenetic regulation in nonsmall cell lung cancer
Mary-Clare Cathcart, Steven G Gray, Anne-Marie Baird, et al.
Scientific Reports
|
July 26, 2019
Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide
John Greene, Anne-Marie Baird, Orla Casey, et al.
International Journal of Cancer
|
April 20, 2007
DOK4/IRS-5 expression is altered in clear cell renal cell carcinoma
Nael Al-Sarraf, Johanne Nørvig Reiff, Jane Hinrichsen, et al.
JAMA Network Open
|
March 9, 2022
Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma
Tomer Meirson, Francesca Pentimalli, Francesco Cerza, et al.
International Journal of Oncology
|
February 16, 2017
Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma
Sian Cregan, Maeve Breslin, Gerard Roche, et al.
International Journal of Oncology
|
March 9, 2005
Altered expression of members of the IGF-axis in clear cell renal cell carcinoma
Masayuki Takahashi, Veronica Papavero, Jason Yuhas, et al.
Plos One
|
January 10, 2013
Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression
Dario Barbone, Priscilla Cheung, Sailaja Battula, et al.
Molecular Cancer
|
January 29, 2020
Correction to: Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer
Martin P Barr, Steven G Gray, Kathy Gately, et al.
Molecular Cancer
|
April 19, 2015
Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer
Martin P Barr, Steven G Gray, Kathy Gately, et al.
Journal of Translational Medicine
|
December 13, 2022
Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology
Tomer Meirson, Valerio Nardone, Francesca Pentimalli, et al.
Page
of 11